DA-302168S

Asset

Activates GLP-1 receptors to promote weight loss and improve cardiometabolic risk factors.

Stage
Phase 2
Modality
Small molecule
Target
GLP1R
1
Indication
0
Trials
1
Developer

Indications

1
  • Overweight or obesity

    Phase 2, doi.org, 5 Jun 2026

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Evidence for its targets2
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets